ClinicalTrialStartPulse: all 1,000 record reports, page 2 of 5

Every ClinicalTrialStartPulse record report, 200 per page, grouped by state. Records 201 to 400: Fujian Medical University Union Hospital: Observational study in Dementia, Alzheimer Dementia (AD) (3000 participants) to Peking Union Medical College Hospital: Observational study in Glycogen Storage Disease (318 participants). Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.

NONUS

• Fujian Medical University Union Hospital: Observational study in Dementia, Alzheimer Dementia (AD) (3000 participants)
• Fujian Medical University Union Hospital: Phase 3 study in Acute Ischemic Stroke, Large Vessel Occlusion (1266 participants)
• Fundació d'investigació Sanitària de les Illes Balears: Phase 3 study in Traumatic Brain Injury (TBI) Patients (536 participants)
• Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau: Not applicable (device, behavioral) study in Falls, Ulcer, Pressure (530 participants)
• Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau: Phase 3 study in Acute Ischemic Stroke, Large Vessel Occlusion (314 participants)
• Fundación Santa Fe de Bogota: Observational study in Breast Neoplasms, Triple Negative Breast Neoplasms (370 participants)
• Fundación Santa Fe de Bogota: Observational study in Overactive Bladder (OAB), Urgency Urinary Incontinence (1700 participants)
• Fundación Santa Fe de Bogota: Observational study in Pain Management, C Section (336 participants)
• Galderma R&D: Not applicable (device, behavioral) study in Cheek Wrinkles, Midface Contour Deficiencies (326 participants)
• GC Biopharma Corp: Phase 3 study in Influenza A, Influenza B, Influenza Vaccination (1806 participants)
• GCS Ramsay Santé pour l'Enseignement et la Recherche: Not applicable (device, behavioral) study in Chronic Kidney Diseases (312 participants)
• GCS Ramsay Santé pour l'Enseignement et la Recherche: Observational study in Exposome, Non-communicable Diseases (NCD) (2500 participants)
• Genentech, Inc.: Phase 1 study in Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma (388 participants)
• General Hospital of Ningxia Medical University: Observational study in Emergence Delirium in Pediatric Anesthesia (470 participants)
• Genfleet Therapeutics (Shanghai) Inc.: Phase 3 study in Colorectal Cancer (368 participants)
• Genmab: Phase 3 study in Ovarian Cancer (602 participants)
• Genoss Co., Ltd.: Not applicable (device, behavioral) study started recruiting, 892 planned (Multi Vessel Coronary Artery Disease, Percutaneous Coronary Intervention)
• George Washington University: Observational study closed enrollment, 1441 enrolled (Type 1 Diabetes Mellitus)
• German Cancer Research Center: Phase 3 study in Non-Small Cell Lung Cancer (406 participants)
• Germans Trias i Pujol Hospital: Observational study in Retinal Artery Occlusion, Central Retinal Artery Occlusion (500 participants)
• Gérond'if: Observational study started recruiting, 5900 planned (Viral Pulmonary Infections)
• GIFT University: Not applicable (device, behavioral) study in Hypertension, Primary Hypertension (1295 participants)
• GlaxoSmithKline: Phase 3 study in Cardiovascular Disease (16390 participants)
• GlaxoSmithKline: Phase 3 study in Endometrial Carcinoma, Neoplasms, Endometrial (378 participants)
• GlaxoSmithKline: Phase 3 study started recruiting, 610 planned (Neoplasms, Endometrial)
• GlaxoSmithKline: Phase 3 study started recruiting, 720 planned (Ovarian Neoplasms)
• Global Institute of Human Development: Not applicable (device, behavioral) study closed enrollment, 600 enrolled (Depression Anxiety Disorder, Psychological Distress)
• Government Super Speciality Hospital, Shireen Bagh, Srinagar: Observational study in Kidney Calculi (or Renal Calculi / Nephrolithiasis), Renal Calculi (688 participants)
• Groupe Oncologie Radiotherapie Tete et Cou: Phase 3 study closed enrollment, 680 enrolled (Squamous Cell Carcinoma of Head and Neck)
• Groupe Oncologie Radiotherapie Tete et Cou: Phase 3 study closed enrollment, 707 enrolled (HNSCC)
• Guangdong Second Provincial General Hospital: Not applicable (device, behavioral) study in Acute Ischemic Stroke, Basilar Artery Occlusion (818 participants)
• Guangzhou Institute of Respiratory Disease: Observational study in Chronic Obstructive Pulmonary Disease (COPD), Traditional Chinese Medicine Syndrome (400 participants)
• Guangzhou Patronus Biotech Co., Ltd.: Phase 3 study in Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection (25000 participants)
• Guangzhou University of Chinese Medicine: Not applicable (device, behavioral) study completed, 542 enrolled (Airway Management, General Anesthesia)
• Guizhou Provincial People's Hospital: Observational study in Endometrial Cancer, Atypical Endometrial Hyperplasia (512 participants)
• Gustave Roussy, Cancer Campus, Grand Paris: Phase 3 study in Osteosarcoma, Pediatric Osteosarcoma (530 participants)
• Guttmacher Institute: Not applicable (device, behavioral) study in Contraceptive Behavior, Self Administration (2736 participants)
• Guttmacher Institute: Not applicable (device, behavioral) study in Contraceptive Behavior, Social Norms (5436 participants)
• Guttmacher Institute: Not applicable (device, behavioral) study in Reproductive Health, Sexual Health (5300 participants)
• Guy's and St Thomas' NHS Foundation Trust: Observational study in Acute Kidney Injury (630 participants)
• HALEON: Observational study in Pain (2100 participants)
• Hamad Medical Corporation: Observational study in Hematological Malignancy, Hematopoetic Stem Cell Transplantation (1000 participants)
• Hamad Medical Corporation: Phase 4 study in Oligoasthenoteratozoospermia, Male Infertility (360 participants)
• Hansoh BioMedical R&D Company: Phase 1 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC) (338 participants)
• Hansoh BioMedical R&D Company: Phase 2 study in Moderate-to-severe Plaque Psoriasis (390 participants)
• Harding Center for Risk Literacy: Not applicable (device, behavioral) study started recruiting, 330 planned (Shared Decision Making, Health Literacy)
• Harvard School of Public Health (HSPH): Not applicable (device, behavioral) study completed, 968 enrolled (Cardiovascular Diseases (CVD))
• Hawler Medical University: Not applicable (device, behavioral) study completed, 1248 enrolled (Morbid Obesity)
• Heart Health Research Center: Not applicable (device, behavioral) study in Heart Failure, Influenza Vaccination (588 participants)
• Hellenic Cooperative Oncology Group: Observational study closed enrollment, 750 enrolled (Breast Cancer)
• Hellenic Cooperative Oncology Group: Observational study in ESR1 Gene Mutation, Breast Cancer (Locally Advanced or Metastatic) (500 participants)
• Hellenic Institute for the Study of Sepsis: Phase 3 study started recruiting, 398 planned (Sepsis)
• Helse Nord-Trøndelag HF: Not applicable (device, behavioral) study in Smoking Cessation, Smoking Cessation Counselling (620 participants)
• Hinova Pharmaceuticals Inc.: Phase 3 study in High Risk Biochemical Recurrence (BCR), Deutenzalutamide Soft Capsules (1044 participants)
• Hoffmann-La Roche: Observational study started recruiting, 1800 planned (Relapsing-Remitting Multiple Sclerosis)
• Hoffmann-La Roche: Phase 1 study in Locally Advanced or Metastatic Solid Tumors (405 participants)
• Hoffmann-La Roche: Phase 1 study in Solid Tumors (540 participants)
• Hoffmann-La Roche: Phase 3 study closed enrollment, 342 enrolled (Hepatocellular Carcinoma)
• Hoffmann-La Roche: Phase 3 study closed enrollment, 451 enrolled (Neovascular Age-related Macular Degeneration (nAMD))
• Hoffmann-La Roche: Phase 3 study in Type 2 Diabetes Mellitus (948 participants)
• Hoffmann-La Roche: Phase 3 study started recruiting, 325 planned (Influenza, Human, Respiratory Tract Infections)
• Hospital Clinico Universitario de Santiago: Not applicable (device, behavioral) study completed, 1036 enrolled (Acute Respiratory Failure, Intubation)
• Hospital del Rio Hortega: Observational study in Hip Fracture (829 participants)
• Hospital Dr Sotero del Rio: Not applicable (device, behavioral) study in Borderline Personality Disorder (BPD), Dialectical Behavior Therapy (360 participants)
• Hospital Universitario La Paz: Observational study in Hepatocellular Carcinoma (HCC) (417 participants)
• Hospital Universitario Ramon y Cajal: Not applicable (device, behavioral) study in Kidney Transplantation, Delayed Graft Function (650 participants)
• Il-Yang Pharm. Co., Ltd.: Phase 3 study in Benign Prostatic Hyperplasia (660 participants)
• Imperial College London: Observational study in Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting (2000 participants)
• Implicity: Observational study in Cardiovascular Diseases (CVD), Cardiac Implantable Electronic Device (CIED) (100000 participants)
• Inha University Hospital: Observational study in Cardiovascular Diseases, Coronary Artery Disease (10000 participants)
• Inha University Hospital: Observational study in Tachycardia, Paroxysmal Supraventricular Tachycardia (10000 participants)
• Innovent Biologics (Suzhou) Co. Ltd.: Phase 1 study in Solid Tumors (604 participants)
• Innovent Biologics (Suzhou) Co. Ltd.: Phase 3 study started recruiting, 520 planned (Atopic Dermatitis)
• Institut Cancerologie de l'Ouest: Observational study in Breast Cancer (312 participants)
• Institut National de la Santé Et de la Recherche Médicale, France: Not applicable (device, behavioral) study in Long COVID Syndrome (618 participants)
• Institut National de la Santé Et de la Recherche Médicale, France: Not applicable (device, behavioral) study in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder (500 participants)
• Institute of Cancer Research, United Kingdom: Observational study closed enrollment, 3500 enrolled (Prostate Cancer, BRCA Mutation)
• Institute of Medical Biology, Chinese Academy of Medical Sciences: Phase 2 study in Diphtheria, Pertussis (380 participants)
• Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz: Not applicable (device, behavioral) study in Depressive Disorder, Major Depressive Disorder, Suicidal Ideation (525 participants)
• Instituto de Investigación Sanitaria Gregorio Marañón: Observational study completed, 1718 enrolled (Bloodstream Infection, Pneumonia - Bacterial)
• International AIDS Vaccine Initiative: Phase 2 study closed enrollment, 5531 enrolled (Tuberculosis (TB))
• International Centre for Diarrhoeal Disease Research, Bangladesh: Not applicable (device, behavioral) study in Depression, Anxiety (1200 participants)
• IRCCS Sacro Cuore Don Calabria di Negrar: Not applicable (device, behavioral) study in Strongyloides Stercoralis Infection, Device Performance (780 participants)
• Istituto Scientifico Italiano Colonna Vertebrale: Observational study in Idiopathic Scoliosis, Adolescent Idiopathic Scoliosis (AIS) (30000 participants)
• iVascular S.L.U.: Observational study in PCI Patients, de Novo Coronary Lesions (5000 participants)
• IWK Health Centre: Not applicable (device, behavioral) study in Developmental Disabilities, Psychological Wellbeing (500 participants)
• Izmir Katip Celebi University: Observational study in Acute Kidney Injury (324 participants)
• Janssen Korea, Ltd., Korea: Observational study in Pulmonary Arterial Hypertension (333 participants)
• Janssen Pharmaceutica N.V., Belgium: Observational study closed enrollment, 1314 enrolled (Arthritis, Psoriatic)
• Janssen Research & Development, LLC: Phase 3 study in Multiple Myeloma (1000 participants)
• Jean-Michel HASCOET: Observational study completed, 1137 enrolled (Bronchiolitis)
• Jeil Pharmaceutical Co., Ltd.: Observational study in Erosive Gastroesophageal Reflux Disease (3000 participants)
• Jena University Hospital: Observational study in Breast Cancer (750 participants)
• Ji-Yeob Choi: Not applicable (device, behavioral) study in Prediabetes, Dietary Self-Management (860 participants)
• Jiangsu Aosaikang Pharmaceutical Co., Ltd.: Phase 3 study in EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (425 participants)
• Jiangsu Famous Medical Technology Co., Ltd.: Not applicable (device, behavioral) study in Colorectal Cancer (1540 participants)
• Jiangsu Hansoh Pharmaceutical Co., Ltd.: Phase 3 study in Chronic Myeloid Leukemia (408 participants)
• Jiangsu Hansoh Pharmaceutical Co., Ltd.: Phase 3 study in SCHIZOPHRENIA 1 (Disorder) (476 participants)
• Jiangsu HengRui Medicine Co., Ltd.: Phase 3 study in Breast Cancer (1050 participants)
• Jiangsu HengRui Medicine Co., Ltd.: Phase 3 study in Diabetes Mellitus, Type 2 (680 participants)
• Jiangsu HengRui Medicine Co., Ltd.: Phase 3 study started recruiting, 480 planned (Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy)
• Jiangsu Simcere Pharmaceutical Co., Ltd.: Phase 3 study in Acute Ischemic Stroke AIS (1092 participants)
• Jiangsu Taizhou People's Hospital: Not applicable (device, behavioral) study in Atrial Fibrillation (AF), Heart Failure (1200 participants)
• Jiangsu Taizhou People's Hospital: Not applicable (device, behavioral) study in Heart Failure (2532 participants)
• Jiangxi University of Traditional Chinese Medicine: Observational study completed, 731 enrolled (Type 2 Diabetes)
• Jiankuan (Suzhou) Biotechnology Company Limited: Phase 3 study in Rheumatoid Arthrits (590 participants)
• Jinling Hospital, China: Observational study in Brown Adipose Tissue, Human (500 participants)
• Johannes Gutenberg University Mainz: Observational study in Airway Assessment (2000 participants)
• Johns Hopkins Bloomberg School of Public Health: Phase 3 study started recruiting, 3000 planned (Neurodevelopment Outcome, Linear Growth)
• Kanuni Sultan Suleyman Training and Research Hospital: Observational study in Postoperative Care (480 participants)
• Kaohsiung Medical University: Observational study in Heart Failure, Fatigue Severity Scale (400 participants)
• Karabuk University: Observational study in Outcome Measurement, Physiotherapy and Rehabilitation (384 participants)
• Kazakh Association of Internal Medicine Specialists: Observational study in Metabolic Dysfunction-Associated Steatotic Liver Disease (420 participants)
• Keymed Biosciences Co.Ltd: Phase 3 study in Multiple Myeloma (MM) (320 participants)
• Khoja Akhmet Yassawi International Kazakh-Turkish University: Not applicable (device, behavioral) study in Acute Respiratory Diseases (400 participants)
• King's College London: Observational study completed, 1020 enrolled (Pregnancy, Antenatal Depression)
• Kite, A Gilead Company: Phase 3 study in Newly Diagnosed Multiple Myeloma (600 participants)
• Kite, A Gilead Company: Phase 3 study in Newly Diagnosed Multiple Myeloma (750 participants)
• Kocaeli City Hospital: Observational study in Acute Respiratory Failure, Critical Illness (1250 participants)
• Kocaeli City Hospital: Observational study in Blood Transfusion (950 participants)
• Konkuk University Medical Center: Not applicable (device, behavioral) study completed, 764 enrolled (Heart Diseases, Vascular Diseases)
• Konstantopoulio-Patission General Hospital of Nea Ionia: Not applicable (device, behavioral) study in Patients Undergoing Gastrointestinal Endoscopy (1300 participants)
• Korea University Anam Hospital: Phase 4 study closed enrollment, 410 enrolled (Coronary Artery Disease, Atherosclerosis of Coronary Artery)
• Kuban State Medical University: Observational study in Internal Carotid Artery Dolichoarteriopathy, Carotid Artery Tortuosity (560 participants)
• Kutahya Health Sciences University: Observational study in Artificial Intelligence, Phlebitis After Infusion (461 participants)
• Lady Reading Hospital, Pakistan: Not applicable (device, behavioral) study in Severe Preeclampsia (434 participants)
• Laval University: Not applicable (device, behavioral) study in Cardiovascular (CV) Risk, Metabolic Health (500 participants)
• Leiden University Medical Center: Not applicable (device, behavioral) study in Liver Disease (Alcoholic or Not), Transplantation (752 participants)
• Linnaeus University: Not applicable (device, behavioral) study in Multimorbidity, Integrated Care (1200 participants)
• Liverpool Heart and Chest Hospital NHS Foundation Trust: Observational study started recruiting, 1200 planned (Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease))
• Liverpool John Moores University: Observational study completed, 790 enrolled (Exertional Heat Illness)
• Liverpool School of Tropical Medicine: Not applicable (device, behavioral) study completed, 600 enrolled (Severe Malaria, Severe Anemia)
• LMC Diabetes & Endocrinology Ltd.: Observational study completed, 3392 enrolled (Diabetes (DM), Type 2 Diabetes)
• LMC Diabetes & Endocrinology Ltd.: Observational study in Obesity, Type 2 Diabetes (T2D) (650 participants)
• London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's: Observational study in Alzheimer's Disease (AD), Cognitive Impairment (1000 participants)
• LuciLab: Phase 3 study completed, 368 enrolled (Risk Behavior, Cognitive Decline)
• Mabsoft Therapeutics (Shanghai) Co., Ltd.: Phase 1 study started recruiting, 420 planned (Neoplams)
• Macfarlane Burnet Institute for Medical Research and Public Health Ltd: Not applicable (device, behavioral) study in Malaria (4350 participants)
• Mälardalen University: Observational study in Knee Osteoarthritis, Physical Activity Behaviour (500 participants)
• Manchester University NHS Foundation Trust: Phase 4 study completed, 657 enrolled (Liver Cirrhosis, Hepatocellular Carcinoma)
• Mansoura University: Not applicable (device, behavioral) study in Web Based Intervention (340 participants)
• Mardin Artuklu University: Observational study in Musculoskeletal Discomfort, Ergonomic Risk Perception (323 participants)
• Masaryk University: Observational study in Familial Hypercholesterolaemia (6276 participants)
• Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.: Not applicable (device, behavioral) study in Perioperative Hypothermia, Inadvertent Perioperative Hypothermia (680 participants)
• McGill University Health Centre/Research Institute of the McGill University Health Centre: Phase 3 study in Pneumocystis Jirovecii Pneumonia (416 participants)
• McMaster University: Not applicable (device, behavioral) study in Guideline Development (741 participants)
• Medical University Innsbruck: Observational study in Sedation Complication, Sedation During GI Endoscopy (500 participants)
• Medical University of Bialystok: Observational study in Decompression Sickness, Barotrauma (384 participants)
• Medical University of Graz: Not applicable (device, behavioral) study in Atrial Fibrillation (AF) (1500 participants)
• Medical University of Vienna: Observational study in Steatotic Liver Disease (20000 participants)
• Medicaweb, S.A.C.V.: Observational study in Cardiovascular Risk Factors, Cardiovascular Diseases (3000 participants)
• Medicines Development for Global Health: Phase 3 study started recruiting, 5100 planned (Lymphatic Filariasis, Scabies)
• MedPacto, Inc.: Observational study in High-Grade Osteosarcoma (400 participants)
• Meir Medical Center: Observational study in Survival to Discharge With Good Neurologic Outcome Among in Hospital Cardiac Arrest Patients (2000 participants)
• Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital: Not applicable (device, behavioral) study closed enrollment, 363 enrolled (Self-Injurious Behavior)
• Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany: Observational study closed enrollment, 366 enrolled (Multiple Sclerosis)
• Merck Sharp & Dohme LLC: Phase 1 study completed, 330 enrolled (Healthy)
• Merck Sharp & Dohme LLC: Phase 1 study in Lower Respiratory Tract Infection (564 participants)
• Merck Sharp & Dohme LLC: Phase 2 study in Pain Management (380 participants)
• Merck Sharp & Dohme LLC: Phase 3 study in Pulmonary Disease, Chronic Obstructive (2136 participants)
• Merck Sharp & Dohme LLC: Phase 3 study in Small Cell Lung Cancer (564 participants)
• Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 930 planned (Papillomavirus Infections)
• Minia University: Observational study in Difficult Airway Management (550 participants)
• Molde University College: Not applicable (device, behavioral) study in Health Literacy, Occupational Health (480 participants)
• Mundipharma (China) Pharmaceutical Co. Ltd: Observational study in Cancer Pain (378 participants)
• Nagasaki University: Observational study in Tuberculosis, Extrapulmonary Tuberculosis (700 participants)
• Nanfang Hospital, Southern Medical University: Observational study in Cataract, Primary Angle-Closure Glaucoma (500 participants)
• Nanfang Hospital, Southern Medical University: Observational study in Musculoskeletal Growth and Development (500 participants)
• Nanjing First Hospital, Nanjing Medical University: Not applicable (device, behavioral) study in Delirium - Postoperative (600 participants)
• Nanjing First Hospital, Nanjing Medical University: Observational study in Colorectal Adenoma, Cholecystectomy (8450 participants)
• Nanjing First Hospital, Nanjing Medical University: Phase 3 study in Helicobacter Infection (612 participants)
• Nanjing Leads Biolabs Co.,Ltd: Phase 2 study started recruiting, 369 planned (Metastatic Colorectal Carcinoma)
• Nanjing Medical University: Observational study in Prediabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) (30000 participants)
• Nantes University Hospital: Not applicable (device, behavioral) study in Uterine Polyps, Uterine Fibroids (474 participants)
• Nantes University Hospital: Observational study in Bacteremia (8765 participants)
• National and Kapodistrian University of Athens: Observational study in Colorectal Diseases, Anal Diseases (400 participants)
• National Cancer Center, Korea: Not applicable (device, behavioral) study in Advanced Solid Tumors, Metastatic Solid Tumors (2800 participants)
• National Cancer Centre, Singapore: Not applicable (device, behavioral) study in Colorectal Cancer (40000 participants)
• National Institute of Allergy and Infectious Diseases (NIAID): Phase 3 study closed enrollment, 5832 enrolled (Tuberculosis, MDR)
• National Institute of Allergy and Infectious Diseases (NIAID): Phase 3 study in Sexually Transmitted Infection (STI), Gonorrhea (580 participants)
• National Institute of Public Health, Clinical Epidemiology, and Toxicology-Lebanon (INSPECT-LB): Not applicable (device, behavioral) study in Older Adults (65 Years and Older), Polypharmacy (People Under Treatment With 5 or More Drugs) (452 participants)
• National Sun Yat-sen University: Observational study in OSA - Obstructive Sleep Apnea, Dysphagia (450 participants)
• National Taiwan University Hospital: Not applicable (device, behavioral) study in Emergency Department, Revisit (4010 participants)
• National University Hospital, Singapore: Not applicable (device, behavioral) study in Brain Injuries (1000 participants)
• National University of Singapore: Not applicable (device, behavioral) study in Focused Strategies to Optimize Sleep, Reduce Sedentary Behaviour, and Enhance Incidental Physical Activity (2000 participants)
• New Valley University: Observational study in Medical Education (1000 participants)
• Nivi, Inc.: Not applicable (device, behavioral) study in Pregnancy, Prenatal Care (2500 participants)
• Norwegian University of Science and Technology: Phase 4 study in Lower Respiratory Tract Infection (LRTI), Recurrent Wheezing (486 participants)
• Nova Scotia Health Authority: Not applicable (device, behavioral) study in Mechanical Ventilation, Cardiac Surgery (336 participants)
• Novo Nordisk A/S: Observational study in Overweight, Obesity (10000 participants)
• October 6 University: Observational study in Acute Coronary Syndrome (1000 participants)
• Odense University Hospital: Not applicable (device, behavioral) study in Cardiovascular Disease, Cardiometabolic Diseases (375 participants)
• Odense University Hospital: Phase 4 study started recruiting, 7000 planned (Ischemic Heart Disease, Ischemic Heart Disease Chronic)
• Onconic Therapeutics Inc.: Phase 3 study in H. Pylori Eradication Therapy (414 participants)
• Oslo Metropolitan University: Observational study closed enrollment, 9836 enrolled (The Focus of the Study is Shift Work)
• Oslo University Hospital: Not applicable (device, behavioral) study started recruiting, 500 planned (Alcoholic Liver Disease (ALD), Alcohol Use Disorder)
• Ottawa Heart Institute Research Corporation: Not applicable (device, behavioral) study closed enrollment, 382 enrolled (Smoking Cessation, Smoking Behaviors)
• Ottawa Heart Institute Research Corporation: Not applicable (device, behavioral) study closed enrollment, 390 enrolled (Infection)
• Patuakhali Science and Technology University: Not applicable (device, behavioral) study in Iron Deficiency Anaemia Due to Dietary Causes, Folic Acid Deficiency Anemia, Dietary (440 participants)
• Peking Union Medical College Hospital: Observational study in Glycogen Storage Disease (318 participants)

Browse ClinicalTrialStartPulse by category and location · Search and filter ClinicalTrialStartPulse